Compare JPMorgan Chase & Co (JPM) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Chase & Co vs Neurocrine Biosciences Inc — how do they compare? JPMorgan Chase & Co trades at $361.65 (market cap $962.37B), while Neurocrine Biosciences Inc trades at $152.36 (market cap $16.46B). The key difference: JPMorgan Chase & Co is far larger — about 58.5× Neurocrine Biosciences Inc's market cap, and JPMorgan Chase & Co pays a 1.66% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| JPM | NBIX | |
|---|---|---|
Market Cap | $962.37B | $16.46B |
Volume | 10,479,943 | — |
Sector | Financials | Health |
52-Week High | $362.04 | $185.50 |
52-Week Low | $282.84 | $123.10 |
Dividend Yield | 1.66% | — |
Enterprise Value | — | $16.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPMorgan Chase (JPM) trades at $359.79, up 0.63% today, with a bullish technical signal from moving averages and a consensus analyst price target of $374.18. Recent earnings show a Q2 2026 beat ($7.59 actual vs. $5.59 expected), though Q4 2025 missed estimates. Revenue grew to $181.85B in 2025, with a net income margin of 33.38% and ROE of 18.43%, but cash flow trends remain volatile with negative net cash flow in 2025.
The outlook is positive with strong profitability and analyst support, but risks include geopolitical tensions affecting oil markets and cybersecurity threats from AI advancements. The stock offers upside to the price target, yet investors should monitor cash flow stability and macroeconomic headwinds highlighted by CEO Jamie Dimon's recent warnings.
Neurocrine Biosciences (NBIX) trades at $163.41, up 2.25% today, with a bearish technical signal but strong fundamentals including a 39% revenue growth in Q2 2026 and a net income margin of 20.91%. Recent news highlights Phase 1 trial initiation for a GLP-1/GIP/glucagon receptor agonist and leadership appointments, supporting growth prospects.
The outlook is positive with an analyst consensus price target of $208.82, implying 28% upside, driven by robust earnings beats and pipeline advancements. Risks include clinical trial outcomes and competitive pressures in biopharma, but institutional buying and high analyst buy ratings (86.49%) reflect confidence in execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
